Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bactelide** is an investigational sustained-release topical bacteriophage cocktail developed by Precisio Biotix Therapeutics for prevention and treatment of antimicrobial-resistant bacterial infections in chronic wounds, initially pressure injuries. The product encapsulates multiple bacteriophages in a biodegradable polymer-based microcapsule delivery system intended to enable penetration and prolonged phage release within the wound bed. Its registered Phase 1/2 study targets pressure injuries colonized by *Staphylococcus aureus*, *Pseudomonas aeruginosa*, or *Klebsiella pneumoniae* as an adjunct to standard wound care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bactelide (Precisio Biotix Therapeutics).